3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
3
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Myelodysplastic Syndromes
26
Hematologic Neoplasms
20
Lymphoma, Non-Hodgkin
19
Multiple Myeloma
18
Lymphoma
18
Recurrence
15
Lymphoma, B-Cell
14
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Breast Neoplasms
11
Pancreatic Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Follicular
10
Neoplasm Metastasis
9
Melanoma
9
Leukemia, Myelomonocytic, Chronic
9
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Biphenotypic, Acute
7
Leukemia
7
Hodgkin Disease
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Osteosarcoma
6
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
fludarabine
×
Clear all
NCT07492628
2026-03-25
DUET-UC-NK
Beijing Biotech
Phase 1
Recruiting
42 enrolled